Search In this Thesis
   Search In this Thesis  
العنوان
Role Of Diffusion Weighted Magnetic Resonance Imaging In Differentiation Between Endometrial Diseases/
المؤلف
Kotb, Maha Hassan Abd El Galel.
هيئة الاعداد
باحث / Maha Hassan Abd El Galel Kotb
mahmoha-3@hotmail.com
مناقش / Hesham Ali Badawy
مناقش / Mohammad Hamdy Zahran
مشرف / Hassan El Prince Hassan
الموضوع
Radiodiagnosis.
تاريخ النشر
2013.
عدد الصفحات
64 p.:
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الطب (متفرقات)
تاريخ الإجازة
6/4/2013
مكان الإجازة
جامعة الاسكندريه - كلية الطب - Radiodiagnosis
الفهرس
Only 14 pages are availabe for public view

from 77

from 77

Abstract

The endometrium demonstrates a wide spectrum of normal and pathologic appearances throughout menarche as well as during the prepubertal and postmenopausal years and the first trimester of pregnancy. Disease entities include polyps, submucosal fibroids, endometrial hyperplasia or endometrial adenocarcinoma.
Endometrial abnormalities are common diagnostic challenges facing the radiologist and referring gynecologist. Although ultrasound (US) is almost always the first modality used in the radiologic work-up of endometrial disease, findings at magnetic resonance imaging, and computed tomography are often correlated with US findings.
DWI is unique non invasive modality has demonstrated the capacity to help discriminate between benign and malignant uterine lesions and to help assess the extent of peritoneal spread from gynecologic malignancies. Potential pitfalls can be avoided by reviewing diffusion-weighted MR imaging findings in conjunction with conventional imaging findings.
Decreased ADC values therefore correlate with increased tumor cellularity and total nuclear area, which act to restrict water diffusion. In general, malignant tumors have a higher cellularity than benign lesions; therefore, ADC values assist in differentiating malignant and benign lesions.
Increasing familiarity with ADC calculation and manipulation software will allow radiologists to provide new information for the care of patients with known or suspected gynecologic malignancies.